Shares rose nearly 4% overnight as investors tied Viking’s upcoming trial and its positioning to renewed obesity-drug deal momentum after Pfizer’s Metsera buyout.
Stocktwits·3d ago
More News
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $27.88, denoting a +1.86% move from the preceding trading day.
Zacks·6d ago
Can NVO Maintain Obesity Leadership With Next-Generation Candidates?
Novo Nordisk is expanding beyond Wegovy and Ozempic with next-generation obesity candidates and strategic deals to defend its market lead.
Zacks·8d ago
Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $25.09, indicating a -5.78% shift from the previous trading day.
Zacks·13d ago
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
Based on the average brokerage recommendation (ABR), Viking Therapeutics (VKTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Zacks·13d ago
Can Viking Therapeutics Hold Its Edge as Obesity Rivalry Heats Up?
VKTX faces rising pressure in the obesity drug race as Pfizer re-enters with a $4.9B Metsera deal and rivals scale up.
Zacks·13d ago
LLY vs. NVO: Which Obesity Drug Stock Is the Better Buy Now?
Eli Lilly's diversified pipeline, rapid tirzepatide growth and rising estimates give it the edge over Novo Nordisk in the obesity drug battle.
Zacks·14d ago
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $24.97, denoting a -4.88% move from the preceding trading day.
Zacks·15d ago
Viking Therapeutics Stock Gets Boost From Pfizer-Metsera Deal, Says BTIG — Retail Slams Rivals For Buying ‘Inferior Pipelines’
BTIG said Pfizer’s $7.3 billion Metsera acquisition sharpens its clinical updates and strategic optionality.
Stocktwits·16d ago
Can Novo Nordisk Hold Its Edge as the GLP-1 Battle With LLY Heats Up?
NVO gains ground in the GLP-1 battle as Ozempic outshines Trulicity in heart risk reduction and Rybelsus wins EU approval for added benefits.